Henoch Schönlein purpura with nephritis in adults: adverse prognostic indicators in a UK population
From the Departments of General and Renal Medicine, and 1Pathology, Manchester Royal Infirmary, Manchester, UK
Address correspondence to Dr F. Ballardie, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL. email: francis.ballardie{at}cmmc.nhs.uk
Received 24 November 2005 and in revised form 27 January 2006
Background: Henoch Schönlein purpura with nephritis (HSN) in adults may cause severe organ injury, but its rarity has contributed to a lack of data.
Aim: To evaluate clinical outcomes and risk factors in adult HSN patients.
Design: Retrospective analysis.
Methods: Thirty-seven patients with adult HSN attending the Regional Vasculitis Clinic between 1974 and 2004 were assessed. For inclusion, a renal biopsy showing predominant mesangial IgA immune deposits was required, plus at least two of: purpuric rash, arthralgia, abdominal pain.
Results: Ten patients (27%) progressed to end-stage renal failure (ESRF). Renal failure rates were highest in the first decade, with survival rate 72% at 5 years, 68% at 10 years and 46% at final review. Risk factors for ESRF were: proteinuria 
1 g/day during follow-up (RR 83.8, p = 0.0006); hypertension at presentation (RR = 53.3, p = 0.0045) and during follow-up (RR = 5.9, p = 0.05); renal impairment at presentation (RR 8.0, p = 0.0015); age <30 years (RR 7.6, p = 0.02); and male sex (RR = 6.0, p = 0.05). Biopsies frequently showed crescents, mostly affecting <50% of glomeruli; their presence predicted ESRF, as did interstitial fibrosis and tubular atrophy. Renal remission, in contrast, was also high (43%). Cytotoxics were used in 32%, with no clear effect on outcome. Relapses affecting the classical extra-renal systems were common, but were not associated with declines in renal function. A high proportion of patients (41%) also suffered vasculitic organ injuries outside the classical systems.
Discussion: HSN in adults is a serious relapsing disease, causing renal failure as frequently as in small-vessel ANCA-positive vasculitides. Prognosis and risks differed in this series from those in other countries, including a higher risk of ESRF than in previous series. Distinct groups developed either ESRF, or remitted. The absence of clear benefit suggests that corticosteroids should be reserved for patients with serious disease, and that cytotoxics may not be merited for those at high risk of renal failure.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. M. Knoll, A. Valles, and M. C. Hogan 56-Year-Old Man With Rash, Abdominal Pain, and Arthralgias Mayo Clin. Proc., June 1, 2007; 82(6): 745 - 748. [Full Text] [PDF]
|
|